Loading...
Back to narrative

ERIS: Board Decisions On Preferential Issue Will Shape Future Market Expansion

India's Shift To Branded Generics Will Expand Chronic Therapy Markets

ERIS logo
ERIS
AnalystConsensusTarget
Not Invested
Published 19 Mar 2025

Update shared on 09 Dec 2025

Fair value Decreased 1.00%
Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
10.2%
7D
-8.5%

Analysts have trimmed their price target on Eris Lifesciences slightly, reducing fair value by about ₹18 to approximately ₹1,789, as they modestly dial back profit margin expectations while leaving growth and discount rate assumptions largely intact.

What's in the News

  • A board meeting is scheduled for November 12, 2025 to review and approve standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025 (Key Developments)
  • A board meeting is set for November 24, 2025 at 14:45 IST to consider issuing equity shares via preferential issue for consideration other than cash, and to initiate shareholder approval through an extraordinary general meeting or postal ballot (Key Developments)
  • A special or extraordinary shareholders meeting will be conducted via postal ballot in India on December 24, 2025 to seek approval related to the planned preferential issue and associated matters (Key Developments)

Valuation Changes

  • Fair Value was trimmed modestly from approximately ₹1,807 to about ₹1,789, reflecting a small downward revision to intrinsic value estimates.
  • The Discount Rate remained unchanged at 12.76%, indicating no shift in the perceived risk profile or cost of capital assumptions.
  • Revenue Growth was nudged up slightly from about 16.08% to 16.09%, suggesting a marginally more optimistic view on top line expansion.
  • The Net Profit Margin was reduced from roughly 22.99% to 22.24%, marking a noticeable downgrade to long term profitability expectations.
  • The Future P/E increased modestly from about 33.05x to 33.81x, implying a slightly higher valuation multiple despite the lower margin outlook.

Have other thoughts on Eris Lifesciences?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.